Less than a year after emerging from stealth operations with $12.7M and partnerships with pharmaceutical giants, Seattle-based biotech startup Accipiter Biosciences has added $10.5M to its funding total. The new cash will let the company move faster on promising drug candidates.
Moving Faster Than Planned, AI Drug Developer Accipiter Bio Quietly Tops Up Seed Round With $10.5M
Share: